CVE-2010-0876 in Industry Product Suite
Summary
by MITRE
Unspecified vulnerability in the Life Sciences - Oracle Clinical Remote Data Capture Option component in Oracle Industry Product Suite 4.5.3 and 4.6 allows remote attackers to affect integrity, related to RDC Onsite.
VulDB is the best source for vulnerability data and more expert information about this specific topic.
Analysis
by VulDB Data Team • 05/17/2025
The vulnerability identified as CVE-2010-0876 resides within the Life Sciences - Oracle Clinical Remote Data Capture Option component of Oracle Industry Product Suite version 4.5.3 and 4.6. This component is designed to facilitate remote data capture for clinical trial data management, making it a critical element in the healthcare and pharmaceutical industry's data processing workflows. The unspecified nature of the vulnerability indicates that the exact technical flaw has not been publicly disclosed in detail, though the impact is clearly defined as affecting data integrity. The vulnerability specifically relates to the RDC Onsite functionality, which represents a key operational aspect of the remote data capture process where data is collected and transmitted from clinical trial sites to central databases.
The technical flaw within the Oracle Clinical Remote Data Capture Option component appears to stem from insufficient validation or protection mechanisms that allow remote attackers to manipulate data during the capture and transmission process. This vulnerability type aligns with CWE-20, which describes improper input validation, and potentially CWE-311, which addresses the lack of encryption for sensitive data. The attack surface is particularly concerning as it involves clinical trial data, which represents highly sensitive information subject to regulatory compliance requirements such as HIPAA and FDA regulations. The RDC Onsite functionality likely handles data transmission between clinical sites and central databases, making it a prime target for adversaries seeking to compromise the integrity of clinical research data.
The operational impact of this vulnerability extends beyond simple data corruption, as it threatens the fundamental reliability and trustworthiness of clinical trial results. When data integrity is compromised, it can lead to incorrect conclusions about drug efficacy or safety, potentially affecting patient health outcomes and regulatory approvals. The remote nature of the attack means that adversaries do not require physical access to clinical sites or network infrastructure, making the vulnerability particularly dangerous. This aligns with ATT&CK technique T1566, which covers credential harvesting and network infiltration methods that can be used to compromise data integrity. Organizations using this software face significant risks including regulatory violations, financial penalties, and reputational damage if clinical data integrity is compromised.
Mitigation strategies for CVE-2010-0876 should focus on immediate patch management and network segmentation. Organizations should prioritize applying Oracle security patches as soon as they become available, though the unspecified nature of the vulnerability may require careful coordination with Oracle support to understand the specific remediation steps. Network-level protections including firewalls, intrusion detection systems, and secure remote access protocols should be implemented to reduce the attack surface. Additionally, organizations should consider implementing data integrity verification mechanisms and regular audits of clinical trial data to detect potential tampering. The vulnerability highlights the importance of maintaining up-to-date security practices in healthcare and pharmaceutical environments where data integrity is paramount. Organizations should also review their incident response procedures to ensure they can effectively detect and respond to data integrity compromises in clinical research environments.